|

PEG-IFNα Clinical Trials

4 actively recruiting trials

Also known as: Pegylated interferon alfa

Pipeline

Phase 2: 3

Top Sponsors

  • The Second Affiliated Hospital of Chongqing Medical University1
  • Minghui Li1
  • Fujian Shengdi Pharmaceutical Co., Ltd.1
  • Brii Biosciences Limited1

Indications

  • Liver Disease4
  • Chronic Hepatitis b3
  • Peg-IFNα1
  • Chronic Hepatitis B Virus (HBV) Infection1
  • Anti-PD-1 Antibody1

Other4 trials

A Multicenter, Randomized, Open, Parallel-designed Study to Evaluate the Efficacy and Safety of HRS-5635 Injection Alone or in Combination With Other Agents in Patients Treated for Chronic Hepatitis B
Phase 2
A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (Sustained HBsAg Loss) (B)
Phase 2
A Study to Evaluate the Efficacy and Safety of Combination Therapy of BRII-179, BRII-835 and PEG-IFNα in Participants With Chronic Hepatitis B Virus (HBV) Infection (ENHANCE)
Phase 2
Exploring the Genome-wide Association Study of the Population With Clinical Cure Advantage in the Treatment of Chronic Hepatitis B With Long-acting Interferon

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.